SENTI 401
Alternative Names: SENTI-401Latest Information Update: 31 Jan 2023
At a glance
- Originator Senti Biosciences
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer T cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Colorectal cancer; Solid tumours
Most Recent Events
- 27 Jan 2023 Pharmacodynamics data from a preclinical studies in Cancer released by Senti Biosciences
- 09 Jun 2022 Preclinical trials in Solid tumours in USA (Parenteral) (Senti Biosciences pipeline, June 2022)
- 11 Apr 2022 Preclinical data presented at American Association for Cancer Research (AACR) Annual Meeting-2022